Resumen
Over the past few years, there has been a notable escalation in scholarly attention towards the implementation of focal therapeutic interventions for patients diagnosed with low- and intermediate-risk prostate cancer in order to achieve long-term cancer control and reduce morbidity associated with surgery and radiation therapy. This interventional pilot study (ClinicalTrials.gov ID NCT04045756) aimed to evaluate the short/medium-term (3 years) efficacy of trans perineal laser ablation (TPLA) in treating the index lesion of low?intermediate-risk prostate cancer, along with assessing the safety of the procedure and Quality of Life (QoL) of patients. Our results suggested that TPLA is a safe, feasible and effective treatment of low?intermediate-risk prostate cancer, with a high rate of tumor eradication and preservation of Quality of Life.